help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ron, D.
Right arrow Articles by Axelrod, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ron, D.
Right arrow Articles by Axelrod, L.

Journal of Clinical Endocrinology & Metabolism, Vol 68, 701-706, Copyright © 1989 by Endocrine Society


ARTICLES

Increased insulin-like growth factor II production and consequent suppression of growth hormone secretion: a dual mechanism for tumor- induced hypoglycemia

D Ron, AC Powers, MR Pandian, JE Godine and L Axelrod
Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Boston 02114.

We investigated the pathophysiology of fasting hypoglycemia associated with large tumors of mesenchymal origin. We studied two patients with symptomatic fasting hypoglycemia (plasma glucose, 1.92 and 2.03 mmol/L) and a large mesenchymal neoplasm. Before therapy, the plasma insulin- like growth factor II (IGF-II) level measured by RIA was elevated (1879 and 1084 micrograms/L; normal range, 358-854 micrograms/L), the serum GH response to hypoglycemia was impaired, and the plasma IGF-I level was low in both patients. After treatment of the tumor, all of these abnormalities resolved in both patients. Northern blot analysis of tumor RNA revealed extremely high levels of IGF-II mRNA (greater than 100-fold higher than those in normal adult liver). Tumor fragments released IGF-II into tissue culture medium (2.1 and 7.2 micrograms IGF- II/g tissue.24 h). These findings indicate that secretion of IGF-II into the circulation by the tumor was the likely source of the elevated plasma IGF-II levels. We suggest that the primary event in tumor- induced hypoglycemia is overproduction of IGF-II by the tumor, which gives rise to hypoglycemia by a dual mechanism: increased glucose utilization mediated by the insulin-like actions of IGF-II and inhibition of GH secretion.


This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
J. W. B de Groot, B. Rikhof, J. van Doorn, H. J G Bilo, M. A Alleman, A. H Honkoop, and W. T A van der Graaf
Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases
Endocr. Relat. Cancer, December 1, 2007; 14(4): 979 - 993.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Miraki-Moud, A. B. Grossman, M. Besser, J. P. Monson, and C. Camacho-Hubner
A Rapid Method for Analyzing Serum Pro-Insulin-Like Growth Factor-II in Patients with Non-Islet Cell Tumor Hypoglycemia
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3819 - 3823.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
M. Fukui, S. Nakamura, H. Sato, T. Matsumoto, N. Nakamura, and M. Kondo
Severe and Recurrent Fasting Hypoglycemia Due to Growth Hormone Deficiency?
Arch Intern Med, September 13, 1999; 159(16): 1954 - 1955.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society